Annual Report

Overview

The report highlights interim efficacy and safety results for evenamide in treatment-resistant schizophrenia, with continued improvement after six months and one year. It records a formal ESG materiality process and identifies ten SDGs for Newron's initiatives. The consolidated financial statements report revenue of 6,094 thousand Euro and a net loss of 17,493 thousand Euro for 2022.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Language: English
Pages
File size

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services